291-OR: Effect of Type 2 Diabetes Characteristics on Semaglutide Treatment in People with Type 2 Diabetes and Peripheral Artery Disease—A Post Hoc Analysis of the STRIDE Trial

IF 7.5 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes Pub Date : 2025-06-21 DOI:10.2337/db25-291-or

NEDA RASOULI, ECENUR GUDER ARSLAN, ANDREI-MIRCEA CATARIG, KIM HOULIND, BERNHARD LUDVIK, JOAKIM NORDANSTIG, HARALD SOURIJ, SEBASTIAN THOMAS, SUBODH VERMA, MARC P. BONACA

{"title":"291-OR: Effect of Type 2 Diabetes Characteristics on Semaglutide Treatment in People with Type 2 Diabetes and Peripheral Artery Disease—A Post Hoc Analysis of the STRIDE Trial","authors":"NEDA RASOULI, ECENUR GUDER ARSLAN, ANDREI-MIRCEA CATARIG, KIM HOULIND, BERNHARD LUDVIK, JOAKIM NORDANSTIG, HARALD SOURIJ, SEBASTIAN THOMAS, SUBODH VERMA, MARC P. BONACA","doi":"10.2337/db25-291-or","DOIUrl":null,"url":null,"abstract":"Introduction and Objective: The STRIDE trial (NCT04560998) demonstrated that once weekly semaglutide 1.0 mg significantly improved maximum walking distance (MWD) in people with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD) vs. placebo. Whether the benefits are consistent across T2D characteristics has not been described. Methods: The primary outcome in STRIDE, MWD measured on a constant load treadmill at 52 weeks, was analyzed by T2D duration (≥10 vs. &lt;10 years), obesity status (BMI (≥30 vs. &lt;30 kg/m2)), glycemic control (HbA1c (≥7% vs. &lt;7%)), and concomitant T2D medications (SGLT2i or insulin). A mixed model for repeated measurements was employed, incorporating treatment, region, and subgroup as fixed factors, along with the treatment-by-subgroup interaction. Baseline values were used as covariates, all nested within each visit. Results: Among 792 randomized STRIDE participants at baseline, median T2D duration was 12.2 years, BMI 28.7 kg/m2, HbA1c 7.1%, with 35.1% on SGLT2i and 31.7% on insulin. Semaglutide significantly improved MWD regardless of T2D duration, BMI, HbA1c and concomitant SGLT2i or insulin use (Figure). Conclusion: These findings support the efficacy of semaglutide in patients with symptomatic PAD across the spectrum of T2D including non-obese participants and those with HbA1c &lt;7%. Disclosure N. Rasouli: Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Eli Lilly and Company. Research Support; Eli Lilly and Company. E. Guder Arslan: Employee; Novo Nordisk A/S, Sanofi. A. Catarig: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. K. Houlind: Consultant; LeMaitre, Novo Nordisk. B. Ludvik: Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Advisory Panel; Novo Nordisk, Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Amgen Inc. Speaker's Bureau; AstraZeneca. Research Support; Eli Lilly and Company. Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. J. Nordanstig: Advisory Panel; AstraZeneca, Novo Nordisk. Other Relationship; Novo Nordisk. H. Sourij: Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Research Support; Eli Lilly and Company. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Daiichi Sankyo. Advisory Panel; Novo Nordisk A/S. Speaker's Bureau; Novo Nordisk A/S. Advisory Panel; Novartis AG, Amarin Corporation, Amgen Inc. S. Thomas: None. S. Verma: Other Relationship; Various. M.P. Bonaca: Other Relationship; CPC Clinical Research. Funding The STRIDE trial was funded by Novo Nordisk A/S","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"48 1","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db25-291-or","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and Objective: The STRIDE trial (NCT04560998) demonstrated that once weekly semaglutide 1.0 mg significantly improved maximum walking distance (MWD) in people with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD) vs. placebo. Whether the benefits are consistent across T2D characteristics has not been described. Methods: The primary outcome in STRIDE, MWD measured on a constant load treadmill at 52 weeks, was analyzed by T2D duration (≥10 vs. <10 years), obesity status (BMI (≥30 vs. <30 kg/m2)), glycemic control (HbA1c (≥7% vs. <7%)), and concomitant T2D medications (SGLT2i or insulin). A mixed model for repeated measurements was employed, incorporating treatment, region, and subgroup as fixed factors, along with the treatment-by-subgroup interaction. Baseline values were used as covariates, all nested within each visit. Results: Among 792 randomized STRIDE participants at baseline, median T2D duration was 12.2 years, BMI 28.7 kg/m2, HbA1c 7.1%, with 35.1% on SGLT2i and 31.7% on insulin. Semaglutide significantly improved MWD regardless of T2D duration, BMI, HbA1c and concomitant SGLT2i or insulin use (Figure). Conclusion: These findings support the efficacy of semaglutide in patients with symptomatic PAD across the spectrum of T2D including non-obese participants and those with HbA1c <7%. Disclosure N. Rasouli: Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Eli Lilly and Company. Research Support; Eli Lilly and Company. E. Guder Arslan: Employee; Novo Nordisk A/S, Sanofi. A. Catarig: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. K. Houlind: Consultant; LeMaitre, Novo Nordisk. B. Ludvik: Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Advisory Panel; Novo Nordisk, Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Amgen Inc. Speaker's Bureau; AstraZeneca. Research Support; Eli Lilly and Company. Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. J. Nordanstig: Advisory Panel; AstraZeneca, Novo Nordisk. Other Relationship; Novo Nordisk. H. Sourij: Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Research Support; Eli Lilly and Company. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Daiichi Sankyo. Advisory Panel; Novo Nordisk A/S. Speaker's Bureau; Novo Nordisk A/S. Advisory Panel; Novartis AG, Amarin Corporation, Amgen Inc. S. Thomas: None. S. Verma: Other Relationship; Various. M.P. Bonaca: Other Relationship; CPC Clinical Research. Funding The STRIDE trial was funded by Novo Nordisk A/S

查看原文本刊更多论文

291-OR: 2型糖尿病特征对2型糖尿病合并外周动脉疾病患者的西马鲁肽治疗的影响——STRIDE试验的事后分析

STRIDE试验（NCT04560998）表明，与安慰剂相比，每周一次的semaglutide 1.0 mg可显著改善2型糖尿病（T2D）和症状性外周动脉疾病（PAD）患者的最大步行距离（MWD）。这些益处在T2D特征中是否一致尚未被描述。方法：STRIDE的主要终点，52周时在恒定负荷跑步机上测量的MWD，通过T2D持续时间（≥10 vs. <；10年）、肥胖状况（BMI(≥30 vs. <30 kg/m2)）、血糖控制(HbA1c（≥7% vs. <7%）和伴随的T2D药物（SGLT2i或胰岛素）进行分析。采用重复测量的混合模型，将治疗、地区和亚组作为固定因素，以及治疗与亚组之间的相互作用。基线值作为协变量，均嵌套在每次访问中。结果：在基线时792名STRIDE随机参与者中，T2D持续时间中位数为12.2年，BMI为28.7 kg/m2， HbA1c为7.1%，其中SGLT2i为35.1%，胰岛素为31.7%。无论t2dm持续时间、BMI、HbA1c和伴随的SGLT2i或胰岛素使用情况如何，Semaglutide都能显著改善MWD（图）。结论：这些发现支持了西马鲁肽对包括非肥胖和HbA1c≥7%的t2dm患者在内的有症状的PAD患者的疗效。N. Rasouli：顾问小组；诺和诺德公司。研究支持;诺和诺德公司。顾问小组;礼来公司。研究支持;礼来公司。E. Guder Arslan：雇员；诺和诺德公司，赛诺菲公司。A.配餐：员工；诺和诺德公司股票/股东;诺和诺德公司K. Houlind：顾问；LeMaitre，诺和诺德。B. Ludvik：研究支持；诺和诺德公司。演讲者的局;诺和诺德公司。顾问小组;诺和诺德，勃林格殷格翰。演讲者的局;勃林格殷格翰集团。研究支持;安进公司。演讲者的局;阿斯利康。研究支持;礼来公司。顾问小组;礼来公司。演讲者的局;礼来公司。J. Nordanstig：咨询小组；阿斯利康，诺和诺德。其他关系;诺和诺德公司。H. Sourij：咨询小组；礼来公司。演讲者的局;礼来公司。研究支持;礼来公司。顾问小组;勃林格殷格翰集团。演讲者的局;第一三共制药。顾问小组;诺和诺德公司演讲者的局;诺和诺德公司顾问小组;诺华公司、Amarin公司、安进公司托马斯：没有。S. Verma：其他关系；不同。博纳卡议员：其他关系；CPC临床研究。STRIDE试验由诺和诺德公司资助

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes 医学-内分泌学与代谢

CiteScore

12.50

自引率

2.60%

发文量

1968

审稿时长

1 months

期刊介绍： Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.